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(ANC>500/mm3)
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Grade aGVHD
% Donor Peripheral Blood
Chimersim/Day
NYMC-
550-
001
11.2 1 Unit 1:
6/6
Unit 1:
2.78105
Alive day
+170
53 days None to date 99% donor 1 Day+100
NYMC-
550-
002
22.5 2 Unit 1:
5/6
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5/6
Unit 1:
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Alive day
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23 days None to date 28% donor 1, 72% donor 2
Day +100
NYMC-
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17.8 2 Unit 1:
4/6
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4/6
Unit 1:
3.58105
Unit 1:
2.51105
Alive day
+52
14 days None to date 59% donor 1, 41% donor 2
Day +30
Abstracts / Biol Blood Marrow Transplant 20 (2014) S128eS150S1386 HLAmatched) with a total nucleated cell (TNC) dose>5.0 x
107 /kg either alone or combined are eligible. The experi-
mental design is depicted in Figure 1B.
Results: To date 3 patients have been transplanted on this
protocol. 1 received a single UCB unit for adrenoleukodys-
trophy (ALD) and 2 received double UCB transplants for acute
lymphoblastic leukemia (ALL). Pre-thaw TNC/kg of HPDSC
were 5.6 x106, 3.9 x106, and 3.1 x106 for patients 1-3
respectively. The characteristics of the pre-thaw UCB are
summarized in Table 1. All 3 patients are alive at 52-170 days
post-transplant with no acute GVHD observed to date and
time to neutrophil engraftment ranging from 14-53 days. In
each case, host and HPDSC chimerisms diminished to low or
undetectable levels over time, but mixed chimerism has
persisted in the double cord blood transplants as far out as
day +100. These results are further summarized in Table 1.
Summary: These data suggest that UCB transplantation in
conjunction with HPDSC infusion is safe and well tolerated
for children with malignant and nonmalignant diseases. A
larger cohort and longer follow-up will be required to
determine the safety and clinical signiﬁcance of these early
ﬁndings. (NCT01586455).189
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Background: Double-unit CB transplantation (DCBT) has
provided high rates of sustained donor engraftment. How-
ever, delayed engraftment is frequent & is associated with
increased transplant-related mortality (TRM).
Methods:We investigated the combined transplantation of a
4-6/6 double-unit CB allograft (infused day 0) with periph-
eral blood derived Miltenyi CD34+ selected haplo-identical
stem cells (haplo-CD34+, infused day 0 or +1) to speed
myeloid recovery. DCB grafts were used to facilitate com-
parison with DCB only controls.
Results: Of 23 eligible patients, 6/23 (26%) had no suitable
haplo-identical donor. Thus, 17 patients (median 39 years,
range 16-69) were transplanted 9/2012-6/2013 with DCB
plus haplo-CD34+ cells for high-risk hematologic malig-
nancies. Conditioning was myeloablative with CSA/MMF
immunosuppression. Median infused CB TNC x 107/kg was
2.29 (larger unit) & 1.82 (smaller unit). 15 patients received 3
x 106/kg CD34+ cells (the targeted dose) whereas 2 each
received 1 x 106/kg. The median infused haplo-CD3+ dose
was 0.6 x 103/kg (range 0.3-1.6). One patient died on day 14.
Of 16 evaluable patients, all (100%) engrafted. The median
neutrophil recovery was 13.5 days (range 11-31) in 14ange)
Day +60
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18 days in 2 patients who received 1 x 106/kg haplo-CD34+
cells. Platelet recovery occurred in 13/16 patients (median 26
days, range 17-46). While day 14 myeloid recovery was
predominantly haplo-mediated, one CB unit dominated by
day 28 in both neutrophil & T-cell subsets (Table). By day 60,
the median total donor chimerism was 100% the dominant
CB unit. With a median survivor follow-up of 7 months
(range 3-12),12/16 patients developed gr. II-IV aGVHD by day
100 (10 gr. II, 1 gr. III, 1 gr. IV). One refractory leukemia patient
relapsed & 5 had TRM (3 organ failure, 1 grade IV aGVHD, 1
CMV infection). Surviving patients were discharged at a 33
day median (9 days faster than DCBT controls).
Conclusions: Double-unit CBT with haplo-CD34+ cells is safe
& neutrophil engraftment is enhanced. A shorter initial
hospitalization offsets the haplo-CD34+ cell cost. It is
intriguing that the dominant CB unit can rapidly reject the
haplo-identical donor. Whether the same results could be
achievedwith single CB units, and whether myeloid recovery
could be further enhanced by a higher haplo-CD34+ cell
dose, require investigation.190
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Background: Availability of suitably HLA-matched unrelated
donors (URD) is a major barrier to allogeneic transplantation
and CB can extend transplant access. We evaluated if URD/
CB access has improved with increased size of URD registries
& global CB inventories.
Methods: We prospectively collected ancestry data on
patients undergoing searches between 10/2005-6/2013, &
analyzed the availability of 9-10/10 HLA-matched URDs or
4-6/6 HLA-A,-B antigen, -DRB1 allele matched CB units by
recipient ancestry. 10 HLA-allele matched URDs were
given priority if available; otherwise HLA-mismatched
URDs or double-unit CB grafts were chosen. This analysis
was restricted to CB units with a cryo. TNC dose > 2.0.
Availability of CB units by 10-allele match was also
evaluated.Early Time Period
(n ¼ 424, 60% of total)
Recent Time Period
(n ¼ 284, 40% of total)
Europeans (n ¼ 485)
N ¼ 295 N ¼ 190
URD: 246 (71% 10/10) URD: 154 (76% 10/10)
CB: 42 (48%  6/10) CB: 35 (54%  6/10)
No graft: 7 (2%) No graft: 1 (0.5%)
Non-Europeans (n ¼ 223)
N ¼ 129 N ¼ 94
URD: 61 (48% 10/10) URD: 50 (56% 10/10)
CB: 46 (28%  6/10) CB: 36 (69%  6/10)
No graft: 22 (17%) No graft: 8 (8.5%)Results: Of 708 patients, 223 (31%) were non-European. URD
recipients were predominantly European (400/511, 78%)
whereas only 77/159 (48%) of CB recipients had European
origins. 30/38 (79%) “no graft” patients were non-European
(including 20 African ancestry patients), and they had a
higher weight (median 93 kg) than CB recipients, p < 0.001.
Graft availability during early (10/2005-12/2010) vs recent
(1/2011-6/2013) periods is shown (Table). Ancestry distri-
bution was equal during the periods. Of all early vs late
period patients, less than two-thirds of Europeans received a
10/10 URD in both eras (59% vs 61%) but very few had no graft
(< 1% recently). However, of non-Europeans in the early
period overall, only 29/129 (22%) had a 10/10 URD, & this has
not improved [28/94 (30%), p¼ 0.28]. While only 28% of non-
Europeans received  6/10 CB units in the early period, this
match rate improved to 69% recently (p < 0.001). The per-
centage of non-Europeans with no graft has decreased from
17% to 8.5% recently (p ¼ 0.08). Of African patients without
an URD, 16/31 (52%) had a CB graft in the early period vs 15/
20 (75%) recently, p ¼ 0.14.
Conclusion: Less than two-thirds of Europeans have a 10/10
URD, but very few do not have an URD &/or CB graft. CB,
unlike URDs, is a critically important donor source for mi-
norities, & transplantation of CB units with higher rates of 10
HLA-allele match is possible. Improved CB availability in
non-Europeans is suggested but an enlarged inventory is
required to extend access, especially for African ancestry
patients.191
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The Killer immunoglobulin-like receptor (KIR) genetic
system is polygenic and highly polymorphic. Several studies
conﬁrmed the KIR haplotype associationwith hematopoietic
stem cell transplant (HSCT) outcome, however, KIR haplo-
type assignment using KIR genotypes, is still a challenge even
with family information available, because KIR haplotypes
may vary in gene copy-number, gene content and allelic
diversity.
The goal of the present study is to assign KIR haplotypes in
related HSCT patient-donor pairs using next generation
sequencing (NGS) method.
We selected 10 families (n¼38 in total): 6 with both parents
available. All of them were previously typed with SSP-
Multiplex for KIR genotyping and Sequencing for 3DL1/2/3
alleles. Scisco KIR NGS method can distinguish KIR geno-
types, calculate gene copy number, estimate gene-content
haplotypes and assign KIR alleles.
KIR genotypes obtained with two methods:SSP and NGS
were identical. We are able to distinguish KIR haplotype
distribution within families. KIR gene copy number is
essential in this regard. However, if a sibling pair are both KIR
AA genotype, it is difﬁcult to distinguish KIR haplotype
matching, without KIR allele information. KIR allele assign-
ments are in progress.192
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